BAM-15
Mitochondrial Uncoupler | Metabolic Enhancer
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.
Mechanism of Action
BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.
Key Benefits
- Increases fat oxidation without affecting food intake
- Reduces body fat mass in research models
- 7-fold more potent than DNP with better safety
- Does not cause dangerous hyperthermia
- No effect on lean body mass
- Improves insulin sensitivity
- Orally bioavailable
- Activates AMPK and PGC-1α pathways
- Synergistic with GLP-1 agonists (semaglutide)
C16H10F2N6O Complex or non-standard sequence format
Metabolic Research
- Obesity/Fat Loss
Reduces body fat by increasing energy expenditure and fat oxidation without reducing food intake.
- Insulin Resistance
Research shows reversal of diet-induced insulin resistance in mouse models.
- Metabolic Syndrome
Addresses multiple components of metabolic syndrome through enhanced energy expenditure.
Combination Therapy Research
- With Semaglutide/GLP-1 Agonists
2024 research shows combining BAM-15 with semaglutide produces stronger metabolic benefits than either alone by countering metabolic adaptation.
- Caloric Restriction Enhancement
May help overcome weight loss plateaus by preventing metabolic adaptation/efficiency.
Other Research Areas
- Liver Triglycerides
Research shows decreased liver triglycerides in treated animals.
- Glucose Tolerance
Improved glucose tolerance observed in research models.
BAM-15 is orally bioavailable and is typically administered as an oral supplement in tablet or capsule form. Research in mice used dietary supplementation (0.1% of diet) or oral gavage dosing. Human dosing protocols are still being established through ongoing research. The compound has a relatively short half-life, which researchers are working to improve through structural modifications.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Metabolic enhancement | 25-50 mg | Once or twice daily | Oral |
| Research protocol (mouse equivalent) | ~10 mg/kg | Daily | Oral gavage |
2024 research shows combination produces stronger metabolic benefits by countering metabolic adaptation that limits GLP-1 efficacy.
Similar synergy expected as with semaglutide; helps overcome weight loss plateaus.
Do not combine with other mitochondrial uncouplers - dangerous additive effects possible.
Both increase metabolic rate; combination requires careful monitoring.
Both affect mitochondrial function but through different mechanisms.
Increased oxygen consumption and metabolic rate
Shift toward fat oxidation (lower respiratory exchange ratio)
Measurable fat mass reduction in research
Improved insulin sensitivity and glucose tolerance
Common Side Effects
- Generally well-tolerated in research
- Possible mild increase in body temperature (less than DNP)
Stop Signs - Discontinue if:
- Significant hyperthermia/overheating
- Excessive sweating
- Rapid heart rate
- Difficulty breathing
Contraindications
- Hyperthyroidism or thyroid disorders
- Heart conditions
- Pregnancy or breastfeeding
- Use of other mitochondrial uncouplers (DNP, FCCP)
- Fever or active infection
Good Signs
- White to off-white powder or tablets
- Certificate of analysis with purity >98%
- Proper packaging protected from light
- Reputable supplier
Warning Signs
- No third-party testing available
- Unclear sourcing
Bad Signs
- Discolored product
- No purity information
- Unknown origin
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.